Dennis Ding
Stock Analyst at Jefferies
(4.09)
# 1,635
Out of 4,649 analysts
93
Total ratings
56.6%
Success rate
12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KARD Kardigan | Initiated Coverage: Buy | $40 | $20.20 | +98.02% | 1 | Jul 13, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $40 | $36.77 | +8.78% | 5 | Jul 10, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $55 → $85 | $84.70 | +0.35% | 4 | Jul 7, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $34.15 | +17.13% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $15 | $4.06 | +269.46% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $125 | $115.48 | +8.24% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Maintained: Buy | $62 | $26.20 | +136.64% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $20.91 | +5.21% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $10.63 | +276.29% | 1 | Mar 19, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $18 → $30 | $36.20 | -17.13% | 16 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $4.67 | +49.89% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $26 | $25.64 | +1.40% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $39.01 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $26.98 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $18 | $41.82 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.41 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $32.95 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $3.16 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $2.73 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $24.71 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $1.90 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $114.47 | n/a | 4 | Feb 14, 2023 |
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $20.20
Upside: +98.02%
Teva Pharmaceutical Industries
Jul 10, 2026
Maintained: Buy
Price Target: $40
Current: $36.77
Upside: +8.78%
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: $55 → $85
Current: $84.70
Upside: +0.35%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $34.15
Upside: +17.13%
Ardelyx
Jun 26, 2026
Maintained: Buy
Price Target: $15
Current: $4.06
Upside: +269.46%
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $125
Current: $115.48
Upside: +8.24%
SpyGlass Pharma
May 19, 2026
Maintained: Buy
Price Target: $62
Current: $26.20
Upside: +136.64%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $20.91
Upside: +5.21%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $10.63
Upside: +276.29%
Roivant Sciences
Feb 9, 2026
Maintained: Buy
Price Target: $18 → $30
Current: $36.20
Upside: -17.13%
Dec 11, 2025
Maintained: Buy
Price Target: $7
Current: $4.67
Upside: +49.89%
Sep 3, 2025
Maintained: Hold
Price Target: $15 → $26
Current: $25.64
Upside: +1.40%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $39.01
Upside: n/a
Jun 11, 2025
Maintained: Buy
Price Target: $45
Current: $26.98
Upside: n/a
May 29, 2025
Maintained: Hold
Price Target: $20 → $18
Current: $41.82
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $2.41
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $32.95
Upside: n/a
Sep 3, 2024
Maintained: Hold
Price Target: $8 → $6
Current: $3.16
Upside: n/a
Jul 17, 2024
Maintained: Hold
Price Target: $1
Current: $2.73
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $24.71
Upside: n/a
Jul 13, 2023
Maintained: Buy
Price Target: $18
Current: $1.90
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $114.47
Upside: n/a